Thorén, Linda http://orcid.org/0000-0003-1541-6191
Margolin, Sara
Eliasson, Erik
Bergh, Jonas
Lindh, Jonatan D.
Funding for this research was provided by:
Cancerfonden (19 0292 PJ 01 H, 19 0189 US01 H)
Percy Falk’s Foundation for research on Prostate Cancer and Breast Cancer
The Swedish Breast Cancer Association
Stockholms Läns Landsting (FoUI- 953166, FoUI-961013, ALF20190536, ALF2017-1341)
Center for Innovative Medicine (963062)
The Research Funds at Radiumhemmet, Karolinska Insitutet (164003)
FOU Karolinska University Hospital (907515)
Karolinska Institute
Article History
Received: 8 December 2022
Accepted: 5 February 2023
First Online: 1 March 2023
Declarations
:
: JB: Research grants from Amgen, AstraZeneca, Bayer, Merck, Pfizer, Roche and Sanofi-Aventis. Grants to Karolinska Institutet and/or University Hospital. No personal payments. Co-author on a chapter in UpToDate on prognostic and predictive factors in early, non-metastatic breast cancer. Honoraria to Asklepios Medicine HB. Presently offered stocks in Stratipath and has been offered to be a consultant for this diagnostic company in early development. The other authors declare no potential conflicts of interest.
: Approval of the study was given by the ethical review board at Karolinska Institutet (Stockholm, Sweden Dnr 02-061, 2014/427-3 and 2016/1698-32).
: Informed consent was obtained from all included patients with biobanked DNA. However, according to our ethical approval, we did not approach the patients again for his specific study.
: Not applicable.